Dapagliflozin (SGLT2 Inhibitor)

What Is Dapagliflozin?

Dapagliflozin (brand name Farxiga in the US, Forxiga elsewhere) is a sodium-glucose co-transporter 2 inhibitor — one of a class of drugs that includes empagliflozin (Jardiance), canagliflozin (Invokana), and henagliflozin. Originally developed for type 2 diabetes, SGLT2 inhibitors have since been approved for heart failure (with and without diabetes) and chronic kidney disease.

The mechanism is elegantly simple: the SGLT2 transporter normally reabsorbs filtered glucose back into the bloodstream from the kidney's proximal tubules. SGLT2 inhibitors block this reabsorption, causing 50-80g of glucose to be excreted in urine daily. This produces caloric loss, mild weight reduction, improved glycemic control, and — as recent research has revealed — striking effects on multiple hallmarks of aging.

The 2025 Telomere Breakthrough

The most consequential SGLT2 inhibitor study of 2025 was published in Cell Reports Medicine (Zhang et al.) — a randomised, double-blind, placebo-controlled trial across 18 Chinese hospitals examining the effects of henagliflozin (10mg/day for 26 weeks) on biological aging markers in 189 type 2 diabetes patients.

The headline finding:

• 90.5% of participants on henagliflozin showed measurable leukocyte telomere lengthening at 26 weeks
• 65.6% of participants on placebo showed any telomere lengthening
• The effect persisted after adjusting for smoking and other confounders

This is the first randomised evidence that any pharmacological intervention can reverse — not just slow — telomere shortening in humans within a 6-month window. Telomere length normally changes slowly over years; a 26-week reversal is unusual and suggests a robust biological signal.

The Senolytic Mechanism

A separate landmark paper (Katsuumi et al., Nature, 2024) demonstrated that SGLT2 inhibitors function as indirect senolytics through a novel mechanism: enhanced immune-mediated clearance of senescent cells.

The mechanism:

1. SGLT2 inhibition upregulates AICAR (5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside)
2. AICAR downregulates PD-L1 expression on senescent cells
3. Senescent cells become visible to immune surveillance
4. Cytotoxic T cells (releasing granzyme B) and NK cells clear them
5. SASP-driven inflammation decreases

This is fundamentally different from Quercetin/Dasatinib senolytics, which work by inhibiting senescent cell pro-survival pathways directly. SGLT2 inhibitors don't kill senescent cells directly — they enable the immune system to recognise and clear them.

The 2025 trial confirmed this in humans: granzyme B (the cytotoxic enzyme T cells use to destroy damaged cells) rose significantly in the henagliflozin group while inflammatory cytokines did not increase — suggesting targeted immune surveillance restoration, not broad immune activation.

The IGF-1 Axis Modulation

The 2025 trial also revealed that henagliflozin increased IGFBP-3 (insulin-like growth factor binding protein 3), which sequesters IGF-1 and reduces its bioavailability. Chronically elevated IGF-1 signalling is associated with accelerated aging in multiple model organisms. Reducing IGF-1 bioavailability shifts the metabolic axis from anabolic growth toward cellular maintenance — a pattern observed in long-lived organisms and caloric restriction models.

SGLT2 as Caloric Restriction Mimetic

The mounting evidence suggests SGLT2 inhibitors function as pharmacological caloric restriction mimetics:

• Force loss of 200-300 kcal/day through glucosuria
• Trigger ketone production (mimicking fasting state)
• Activate AMPK and SIRT1 (caloric restriction pathways)
• Increase autophagy markers
• Reduce inflammation markers
• Decrease IGF-1 bioavailability

This combination of effects approximates caloric restriction without the requirement to restrict caloric intake — though the magnitude of effects is more modest than true caloric restriction in animal models.

Cardiovascular and Renal Benefits

Beyond the longevity mechanisms, SGLT2 inhibitors have demonstrated dramatic cardiovascular and renal benefits in dedicated trials:

• DAPA-HF (NEJM 2019): 26% reduction in cardiovascular death or worsening heart failure
• EMPEROR-Preserved (NEJM 2021): Benefits in heart failure with preserved ejection fraction
• DAPA-CKD (NEJM 2020): 39% reduction in renal events
• EMPA-KIDNEY (NEJM 2023): Benefits in broader CKD populations

These benefits appear independent of glycemic control — observed in patients without diabetes. The cardiovascular protection alone justifies use in many longevity-focused individuals.

Side Effects and Safety

The most common side effect is genital mycotic infection (yeast infections) — affecting 5-15% of users due to elevated glucose in urine creating a favourable environment for fungal growth. Risk is higher in:

• Women
• Uncircumcised men
• Individuals with diabetes
• Poor hygiene

Most cases respond to standard antifungal treatment without discontinuation of the medication.

Less common concerns:

• Euglycemic DKA — rare but serious; risk significantly increased on strict ketogenic diet
• Volume depletion — particularly in elderly or those on diuretics
• UTI — modest increase vs placebo
• Fournier's gangrene — very rare but serious; immediate medical attention for any perineal symptoms

Longevity vs Diabetes Dosing

For diabetic patients, 10mg/day is the standard maintenance dose.

For longevity-focused use in non-diabetic individuals, several approaches:

• 5mg/day — most benefits with reduced infection risk
• 10mg every other day — half-effective dose with reduced side effect risk
• 10mg/day — full dose if tolerating well

Lower doses preserve most of the metabolic and longevity benefits while reducing side effect risk. The exact optimal dose for longevity in non-diabetics has not been formally established.

Stacking Recommendations

SGLT2 inhibitors pair well with:

• Berberine — both AMPK activators, complementary metabolic effects
• NMN/NR — NAD+ support amplifies SIRT1 activation
• Urolithin A — mitophagy + immune-mediated senolytic effects
• Omega-3 — cardiovascular synergy
• Quercetin/Fisetin — different senolytic mechanism, potentially complementary

Caution with:

• Strict ketogenic diet — euglycemic DKA risk
• Rapamycin — both reduce immune function; combination requires careful monitoring

Related Research

• SGLT2 Inhibitors: The First Drugs That Reverse Telomere Aging in Humans
• The Senolytic Stack 2026: Quercetin + Fisetin + SGLT2 Combined Protocol